Loading...
Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Loading earnings analysis...
Compass Score
Favorable
Key Numbers
Market Cap
$30B
P/E
N/A
Revenue Growth
+40.0%
Gross Margin
N/A
ROE
N/A
About Alnylam Pharmaceuticals
As a mid-cap biotech company trading on the NASDAQ, Alnylam Pharmaceuticals has established itself, with direct, concentrated exposure to the biotech and genomics theme. RNA interference therapeutics leader with approved treatments for rare diseases. With a $30B market capitalization and no current profitability, the company demonstrates exceptional revenue growth at +40% year-over-year.
Expert Coverage
Unlock Full ALNY Analysis
Expert analysis and coverage for Alnylam Pharmaceuticals
Or unlock everything now with Compass, $9/moPrice & Technical Analysis
Price50 DMA200 DMA
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
Rating last updated: 2026-06-21
More in Biotech & Genomics
BEAM
Beam Therapeutics
90
True North
Pure Play
Base editing platform with differentiated gene-editing pipeline.
NASDAQ
MCap $3BDXCM
DexCom Inc.
90
True North
Pure Play
Continuous glucose monitoring leader expanding beyond diabetes management.
NASDAQ
MCap $35BRev +20%P/E 55RXRX
Recursion Pharmaceuticals
88
True North
Pure Play
AI-driven drug discovery platform using machine learning to decode biology at scale.
NASDAQ
MCap $4BRev +55%CRSP
CRISPR Therapeutics
86
True North
Pure Play
Pioneer of CRISPR gene-editing therapy with first approved treatment for sickle cell disease.
NASDAQ
MCap $5BRev +350%